T2D Research

PBMC Immune Changes in Type 2 Diabetes

Properties2
tagsconcept, type-2-diabetes, pbmc, immunology, literature-review
aliasesPBMC Immune Changes in Type 2 Diabetes

6 min read

PBMC Immune Changes in Type 2 Diabetes

This page is the hub for claims about immune changes observed in PBMC from people with type 2 diabetes. Treat this as a claim register until enough references have been ingested.

Claim Register

ClaimEvidenceStatusNotes
T2D is associated with measurable PBMC immune differences.Gu et al. 2024single-studyGu et al. 2024 observed altered cell composition and cell-state changes in 293,923 PBMCs from Korean non-diabetes and T2D participants.
T2D CD14 monocytes show a stronger inflammatory state.T2D Monocyte Inflammatory Signaturesingle-studyGu et al. 2024 report higher pro-inflammatory scores and pseudobulk inflammatory-gene expression in T2D CD14 monocytes.
T2D cytotoxic T-cell subsets show higher cytotoxicity and clonal expansion.T2D Cytotoxic T-Cell Expansionsingle-studyGu et al. 2024 report higher cytotoxicity scores, KLRG1 expression in CD8 Tem, and higher cytotoxic T-cell Gini clonality.
T2D B-cell states shift toward intermediate B cells, plasma cells, and isotype diversity.T2D B-Cell Differentiation and Isotype Switchingsingle-studyGu et al. 2024 report lower naive B-cell proportions and higher intermediate B-cell, plasma-cell, and BCR isotype-diversity features.
Bulk blood and PBMC transcriptomic T2D signatures show low cross-study concordance.Tkachenko et al. 2025multi-study meta-analysisTkachenko et al. 2025 analyzed eight blood RNA-seq datasets and found that four had zero DEGs, only five DEGs were directionally shared across the three DEG-rich studies, and meta-analysis recovered 2065 DEGs.
NK cell proportions in T2D PBMCs vary across studies.T2D NK Cell Composition in PBMCs; Tkachenko et al. 2024single-study preprintTkachenko et al. 2024 found NK cells significantly less prevalent in T2D PBMCs by DCATS analysis (n=2/group), contrasting with Gu et al. 2024. The authors attribute this discrepancy to small sample size.
CD4+ TCM and naive cells increase in T2D PBMCs.Tkachenko et al. 2024single-study preprintDCATS analysis showed CD4+ TCM and naive cells significantly more abundant in T2D.
Bulk blood T2D transcriptomic signal is weak relative to non-disease variance.Tkachenko et al. 2024; T2D Bulk Blood Transcriptome Signal-to-Noisesingle-study preprintPCA of top 500 most variable genes shows no T2D group separation; only 146 DEGs out of 74K genes.
T2D PBMC changes include T-cell immunometabolic heterogeneity and subtype-specific T-cell-monocyte communication.Li et al. 2025single-study reanalysisLi et al. 2025 combined T2D cells from GSE268210 with healthy controls from GSE244515 and defined T2D subtypes A-C from T-cell metabolic pathway GSVA scores.
T2D PBMC T cells and monocytes show inflammatory pathway associations in a small Chinese scRNA-seq cohort.Zhao and Fang 2025; NF-kB and IFN-Gamma Signalingexploratory single-studyZhao and Fang 2025 report 119 T-cell DEGs and 175 monocyte DEGs, with pathway findings involving TNF/NF-kB, interferon-gamma response, T-cell receptor signaling, and chemokine signaling in a 3 T2DM versus 3 control cohort.
Some PBMC findings may vary by ancestry or cohort composition.Pending source ingestionhypothesisLink to ancestry-associated immune differences.

Dimensions To Separate

  • Cell proportions versus per-cell state.
  • Innate immune signatures versus adaptive immune signatures.
  • Baseline immune state versus stimulated response.
  • T2D effect versus obesity, age, sex, medication, infection, or socioeconomic confounding.
  • Ancestry-associated signal versus batch, site, geography, and recruitment differences.

Evidence To Collect

  • PBMC cytometry studies in T2D.
  • Bulk PBMC transcriptomics in T2D.
  • Single-cell PBMC studies in T2D or insulin resistance; Gu et al. 2024 is the first ingested example.
  • Studies with ancestry-aware analysis, multi-ancestry cohorts, or ancestry-stratified results.
  • Negative or null studies that constrain the argument.

Source-Backed Pattern From Gu et al. 2024

  • Gu et al. 2024 shows that single-cell PBMC profiling can separate T2D-associated cell-proportion shifts from per-cell state changes.
  • Gu et al. 2024 describe a coordinated monocyte, T-cell, and B-cell pattern that may contribute to chronic inflammation in T2D, but causal ordering remains unresolved.
  • Gu et al. 2024 does not directly address ancestry-associated differences, so it should support the T2D/PBMC background rather than the ancestry-specific claim.

Source-Backed Pattern From Tkachenko et al. 2025

  • Tkachenko et al. 2025 constrains PBMC immune claims by showing that blood transcriptomic signatures in T2D can vary strongly across cohorts, sample types, and technical protocols.
  • Tkachenko et al. 2025 links T2D blood transcriptomic signal to neutrophil effector biology, ERAD, mTOR signaling, oxidative stress, and RNA splicing, but neutrophil-specific findings should be transferred to PBMC interpretation cautiously because PBMC excludes most mature neutrophils.

Source-Backed Pattern From Li et al. 2025

  • Li et al. 2025 reports higher monocyte proportions, lower CD4+ T-cell proportions, higher intermediate monocytes, and altered T-cell subtype proportions in T2D PBMC single-cell data.
  • Li et al. 2025 adds an immunometabolic layer by defining T2D T-cell immunometabolic subtypes from 42 KEGG metabolic pathway GSVA scores.
  • Li et al. 2025 reports stronger inferred T-cell-monocyte communication in T2D, especially MHC-I signaling across subtypes and broad subtype B signaling through CD30, CD48, TGF-beta, IFN-II, TNF, and CCL pathways.
  • Li et al. 2025 reuses GSE268210 and adds healthy controls from GSE244515, so it strengthens T2D/PBMC mechanistic framing but does not resolve ancestry-specific questions.

Source-Backed Pattern From Huang et al. 2022

  • Huang et al. 2022 provides a complementary pancreatic islet transcriptome perspective — identifying tissue-level biomarkers (SLC2A2, SERPINF1, RASGRP1, CHL1) and a pancreatic fibroblast SERPINF1-NR2F2 regulatory axis. This is not PBMC evidence but offers cross-tissue context for T2D molecular pathology.
  • Huang et al. 2022 T2D islet DEGs enrich for JAK-STAT and Ras signaling, pathways also implicated in immune regulation — suggesting shared signaling themes between islet pathology and PBMC immune remodeling in T2D.

Source-Backed Pattern From Tkachenko et al. 2024

Source-Backed Pattern From Zhao and Fang 2025

  • Zhao and Fang 2025 provides a small single-center Chinese PBMC scRNA-seq study that retained 13,591 cells and focused downstream analysis on T-cell and monocyte DEGs.
  • Zhao and Fang 2025 links T-cell DEGs to TNFA signaling via NF-kB, T-cell receptor signaling, and TNFRSF1A-centered network interactions.
  • Zhao and Fang 2025 links monocyte DEGs to interferon-gamma response and chemokine signaling, with CLEC2B, B2M, and MALAT1 highlighted as shared genes in one WGCNA module.
  • The source reinforces inflammatory pathway themes in T2D PBMCs but should be treated as exploratory because it has n=3 per group, single-center recruitment, and no ancestry modeling.

Graph View

Backlinks